Cerity Partners LLC Buys Shares of 11,006 Hims & Hers Health, Inc. (NYSE:HIMS)

Cerity Partners LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,006 shares of the company’s stock, valued at approximately $325,000.

Several other hedge funds and other institutional investors have also bought and sold shares of HIMS. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company’s stock valued at $30,878,000 after purchasing an additional 1,098,148 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $57.50 on Monday. The business’s 50-day moving average is $53.15 and its two-hundred day moving average is $43.00. The company has a market capitalization of $12.87 billion, a P/E ratio of 83.33, a P/E/G ratio of 2.13 and a beta of 2.02. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm had revenue of $586.01 million for the quarter, compared to analysts’ expectations of $535.21 million. During the same period last year, the firm earned $0.05 EPS. The company’s quarterly revenue was up 110.7% on a year-over-year basis. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other news, insider Michael Chi sold 2,100 shares of the firm’s stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the sale, the insider directly owned 278,654 shares in the company, valued at $16,028,178.08. This trade represents a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 125,335 shares of the firm’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $49.54, for a total value of $6,209,095.90. Following the sale, the chief executive officer owned 92,313 shares in the company, valued at $4,573,186.02. This trade represents a 57.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 785,132 shares of company stock valued at $42,312,559 over the last quarter. Insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Morgan Stanley reiterated an “equal weight” rating and set a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Piper Sandler restated a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $39.83.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.